Risperidone: An open-label observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 25, Issue 4, 2005, Pages 293-300

  Pajonk, Frank Gerald ^a   Schreiner, Andreas ^b   Peters, Stefan ^b   Rettig, Klaus ^c   Degner, Detlef ^d   Rüther, Eckart ^d  

^a SAARLAND UNIVERSITY   (Germany)

^b JANSSEN CILAG GMBH   (Germany)

^c Medizin Mbh ^*  (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; OPEN STUDY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HOSTILITY; HUMANS; MALE; MIDDLE AGED; OBSERVATION; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 23044479627     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000170686.27476.ab     Document Type: Article

References (45)

1. Malla AK, Norman RM, Manchanda R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res. 2002;54:231-242.
2. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia The effects of dose reduction and family treatment. Arch Gen Psychiatry. 1997;54:453-463.
3. Ananth J, Parameswaran S, Hara B. Drug therapy in schizophrenia. Curr Pharm Des. 2004;10:2205-2217.
4. Binder RL, McNiel DE. Emergency psychiatry: contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatr Serv. 1999;50:1553-1554.
5. Ereshefsky L. Use of intramuscular antispychotics in acute-care settings Poster presented at the 152nd Annual Meeting of the American Psychiatric Association, Washington DC, May 15-20, 1999.
6. Möller HJ. Current assessment of new/atypical neuroleptic agents. Nervenarzt. 2000;71:329-344.
7. Naber D, Lambert M, Krausz M, et al. Atypical Antipsychotics in the Treatment of Schizophrenic Patients. Bremen: UNI-MED Science; 2002.
8. Raja M, Azzoni A. Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study. Gen Hosp Psychiatry. 2000;22:107-114.
9. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996;16:38-44.
10. Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993;88:395-402.
11. Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand. 1995;91: 271-277.
12. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
13. Pajonk FG. Risperidone in acute and long-term therapy of schizophrenia - a clinical profile. Prog Neuro-Psychopharmacol Biol Psychiatry. 2004;28:15-23.
14. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993;26:121-124.
15. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62: 153-157.
16. Beck NC, Greenfield SR, Gotham H, et al. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. J Am Acad Psychiatry Law. 1997;25:461-468.
17. Buckley PF, Ibrahim ZY, Singer B, et al. Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry Law. 1997;25:173-181.
18. Chengappa KN, Levine J, Ulrich R, et al. Impact of risperidone on seclusion and restraint at a state psychiatric hospital. Can J Psychiatry. 2000;45:827-832.
19. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol. 1995;15:243-249.
20. Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000; 61(suppl 3):4-9.
21. Raedler TJ, Schreiner A, Naber D, et al. Risperidone in the treatment of acute schizophrenia. J Clin Psychopharmacol. 2004;24:335-338.
22. Currier GW. Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry. 2000;61(suppl 14):21-26.
23. McCreadie RG. Managing the first episode of schizophrenia: the role of new therapies. Eur Neuropsychopharmacol. 1996;6(suppl 2):S3-S5.
24. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
25. Kane JM. Factors which can make patients difficult to treat. Br J Psychiatry Suppl. 1996:10-14.
26. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry. 2001;158:266-269.
27. Linden M, Baier D, Beitinger H, et al. Guidelines for the implementation of drug utilization observation (DUO) studies in psychopharmacological therapy. The "Phase IV Research" Task-Force of the Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP). Pharmacopsychiatry. 1997;30:65-70.
28. Pajonk FG, Schreiner A, Peters S, et al. Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients - an interim analysis. Fortschr Neurol Psychiatr. 2003;71:249-254.
29. Kay S, Opler L, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) Manual. North Tohawanda, NY: Multi-Health Systems; 1986.
30. Gerlach J. Life is not so easy. Individualization in clinical psychopharmacology. Psychopharmacology (Berlin). 2002;162:1-2.
31. Lambert T, Kelly DL, Alcock S, et al. Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis. J Clin Psychopharmacol. 2004;24:91-93.
32. Pajonk FG, Holzbach R, Naber D. Comparing the efficacy of atypical antipsychotics in open uncontrolled versus double-blind controlled trials in schizophrenia. Psychopharmacology (Berlin). 2002;162:29-36.
33. Karavias GA. Long-term treatment of schizophrenia with risperidone: an international multicenter, open label trial. New Trends Exp Clin Psychiatry. 1998;14:165-171.
34. Kopala LC, Good KP, Fredrikson D, et al. Risperidone in first-episode schizophrenia: improvement in symptoms and pre-existing extrapyramidal signs. Int J Psychiatry Clin Pract. 1998;2(suppl 1):19-25.
35. Peuskens J, Bech P, Möller HJ, et al. Amisulpiride versus Risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res. 1999;88:107-117.
36. Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol. 2003;23:342-348.
37. Ritsner M, Kurs R, Ponizovsky A, et al. Perceived quality of life in schizophrenia: relationships to sleep quality. Qual Life Res. 2004;13: 783-791.
38. Aleman A, Kahn RS. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur Neuropsychopharmacol. 2001;11:289-293.
39. National Institute for Clinical Excellence (NICE) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance No 43. London: National Institute for Clinical Excellence; 2002.
40. Merlo MC, Hofer H, Gekle W, et al. Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry. 2002;63:885-891.
41. Campbell R, Simpson GM. Alternative approaches in the treatment of psychotic agitation. Psychosomatics. 1986;27:23-27.
42. Dubin WR. Rapid tranquilization: antipsychotics or benzodiazepines? J Clin Psychiatry. 1988;49(suppl):5-12.
43. Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol. 1997;12:175-179.
44. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Second edition. Am J Psychiatry. 2004: 1-114.
45. McGorry P, Killackey E, Elkins K, et al. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia. Australas Psychiatry. 2003;11:136-147.